Part 4/Chapter 18/8-min read

Aneurysm Biology, Screening, Surveillance, and Decision Frameworks

AAA care is an ordered sequence of decisions: identify people who benefit from one-time ultrasound, measure the infrarenal aorta consistently, place small aneurysms into structured surveillance, move to repair when diameter, growth, morphology, symptoms, or patient fitness changes the balance, and continue imaging after EVAR to detect late failure.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·7 sections · 24 references

Listen to this chapter6 min · AI audio edition · two hostsAI narration

Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.

General medical education, not patient-specific advice.

Choose the hosts

Definition and presentation

An abdominal aortic aneurysm is an infrarenal aortic diameter of 3.0 cm or greater, measured consistently by ultrasound or cross-sectional imaging . The condition reflects a chronic degenerative process of the aortic wall, strongly influenced by age, smoking exposure, sex, family history, and systemic atherosclerosis.

Most small aneurysms are clinically silent and are detected incidentally or through population screening. The principal risk is rupture, which rises steeply with increasing diameter.

Estimated annual rupture risk climbs sharply across diameter bands:

Surveillance<4.0 cm
<4.0 cm
Estimated annual rupture risk
0%
4.0 to 4.9 cm
Estimated annual rupture risk
0.5 to 5%
5.0 to 5.9 cm
Estimated annual rupture risk
3 to 15%
6.0 to 6.9 cm
Estimated annual rupture risk
10 to 20%
7.0 to 7.9 cm
Estimated annual rupture risk
20 to 40%
>= 8.0 cm
Estimated annual rupture risk
30 to 50%

These estimates anchor the surveillance-versus-repair balance . The clinical implication of a given diameter is modified by several features:

  • Growth rate
  • Saccular morphology
  • Presence of symptoms
  • Patient size and sex
  • Operative fitness

Screening and population trials

Population screening targets groups with a high pre-test probability to detect clinically important aneurysms via one-time abdominal ultrasound. The strongest mortality benefit is observed in older men with a history of smoking.

In the MASS (2002) trial of community-dwelling men aged 65 to 74 years, an invitation for a one-time ultrasound screening demonstrated a 42% relative risk reduction in aneurysm-related mortality at four years, an effect that persisted at 10 and 13 years . Pooled evidence syntheses report long-term mortality odds ratios of 0.60 to 0.65 in screened older men .

Risk FactorsScreening eligibility by target population
Men 65 to 75 years
Risk factor
Ever-smokers (>= 100 lifetime cigarettes)
Recommendation
Routine one-time abdominal ultrasound
Citation
Men 65 to 75 years
Risk factor
Never-smokers
Recommendation
Selective screening
Citation
Women 65 to 75 years
Risk factor
Smoking or family history
Recommendation
Insufficient evidence for routine screening
Citation
Women 65 to 75 years
Risk factor
No smoking or family history
Recommendation
Recommend against routine screening
Citation

Diagnosis and surveillance

Immediate open repair of small aneurysms (4.0 to 5.5 cm) provides no survival benefit over surveillance. In the UKSAT (2002) trial, immediate repair yielded a hazard ratio of 0.94 for all-cause mortality with a 5.8% 30-day operative mortality compared to observation . Consequently, identified aneurysms below the repair threshold are managed with scheduled imaging.

Surveillance intervals scale inversely with aneurysm diameter. Aneurysms are tracked using consistent ultrasound methodology, transitioning to computed tomography or magnetic resonance angiography when ultrasound windows are poor or anatomy mapping is required for repair planning . Pooled aneurysm growth rates average 2.38 mm per year . Apparent rapid interval growth of >= 10 mm per year requires remeasurement with the same imaging modality to exclude measurement noise before advancing to repair.

Surveillance scheduleBorderline (2.5 to 3.0 cm)
  • 01Borderline (2.5 to 3.0 cm)
    Modality
    Ultrasound
    Reassessment interval
    10 years
    Citation
  • 02Small (3.0 to 3.9 cm)
    Modality
    Ultrasound
    Reassessment interval
    36 months
    Citation
  • 03Medium (4.0 to 4.9 cm)
    Modality
    Ultrasound
    Reassessment interval
    12 months
    Citation
  • 04Large (5.0 to 5.4 cm)
    Modality
    Ultrasound
    Reassessment interval
    6 months
    Citation
  • 05Rapid growth (>= 10 mm/year)
    Modality
    Initial modality
    Reassessment interval
    Prompt re-measurement before intervention
    Citation

Medical management

Medical therapy is directed at cardiovascular risk reduction rather than aneurysm-specific growth modification. Smoking cessation is the single most effective modifiable intervention and carries a strong SVS recommendation: continued smoking accelerates aneurysm expansion and raises rupture risk, so every current smoker with an AAA should be supported to quit . Statins are recommended for cardiovascular prevention and are associated with lower perioperative mortality during aneurysm repair. Observational data associate statin use with a mean growth-rate reduction of 0.82 mm per year, but heterogeneity limits their use as an aneurysm-specific indication .

Fluoroquinolone exposure is observationally associated with a higher short-term risk of aortic events (relative risk 9.13). Alternative antibiotics are utilized when feasible in patients with known aortic disease . Metformin demonstrates an inverse observational association with aneurysm presence and growth (approximately 0.8 mm per year lower), but no trial evidence supports initiating glucose-lowering therapy solely for aneurysm control .

Treatment decisions and repair thresholds

Elective repair is indicated when the predicted rupture risk during continued observation exceeds the combined risk of intervention. Treatment choices follow an ordered pathway governed by absolute diameter, anatomy, and procedural fitness.

Decision threshold

Elective repair thresholds and management pathways

  1. Observation
    Below dimension threshold and asymptomatic
    Scheduled ultrasound surveillance
  2. Medical therapy
    Established diagnosis
    Statin therapy for cardiovascular risk
  3. Elective repair (men)
    Fusiform diameter >= 5.5 cm (SVS) or >= 55 mm (ESVS)
    Refer for elective repair planning
  4. Elective repair (women)
    Fusiform diameter 5.0 to 5.4 cm (SVS)
    Refer for elective repair planning
  5. Saccular morphology
    Any dimension with saccular anatomy
    Earlier repair assessment regardless of absolute diameter
  6. Prohibitive risk
    Unfit for operative repair
    Palliative or watchful surveillance
  7. Emergency
    Rupture, impending rupture, or severe symptoms
    Urgent intervention pathway
Source · · ·

The management logic proceeds stepwise:

  1. Decide surveillance versus repair. Asymptomatic aneurysms below society thresholds are managed with scheduled imaging. Repair is planned when the maximum diameter reaches >= 5.5 cm for men or 5.0 to 5.4 cm for women, or when saccular morphology overrides dimensional rules.
  2. Optimize medical management. Cardiovascular risk is modified for all patients, integrating statins and avoiding fluoroquinolones where feasible.
  3. Select endovascular versus open repair. Endovascular aneurysm repair is preferred when the anatomy offers adequate proximal seal-zone length, acceptable neck angulation, and sufficient iliac access calibre. Open repair is favoured for patients with prohibitive neck angulation, severe calcification or thrombus in the seal zone, or inadequate access vessels who remain physiologically fit for open surgery.
  4. Address emergency modifiers. Symptomatic presentation, tenderness, embolic events, or rapid expansion bypass elective sizing and force immediate surgical evaluation.
  5. Confirm no-intervention candidacy. Patients who are entirely unfit for the physiologic stress of intervention are assigned to watchful waiting, independent of aneurysm size.

Special populations and post-repair surveillance

Patient sex, family history, and regional prevalence influence baseline risk and pathway management. Women generally present with lower overall prevalence but display worse short-term outcomes following endovascular repair, including elevated odds of 30-day and in-hospital mortality in pooled analyses . Repair thresholds are correspondingly downshifted for women.

First-degree family history alters pre-test probability and selectively prompts screening evaluation. Asian populations demonstrate an overall aneurysm prevalence of 1.30%, escalating to 2.56% in subsets with high cardiovascular risk. This regional variation informs specific regional frameworks, such as the KVSS threshold band of 50 to 55 mm for elective repair in men .

Endovascular repair commits the patient to lifelong surveillance to assess seal zones, sac geometry, and complications such as endoleak or device migration. Computed tomography angiography remains the foundational modality because it comprehensively maps branch vessels and device position. Contrast-enhanced colour duplex ultrasound offers high diagnostic accuracy (pooled sensitivity 0.94, specificity 0.95 for endoleak) and is used to reduce cumulative radiation and contrast exposure in stable patients . Changes in sac volume identify expansion missed by maximum diameter alone . Although late rupture after endovascular repair is uncommon (cumulative incidence 0.9%, mean time to event 37 months), it carries high perioperative mortality (32%) and reinforces the necessity of structured surveillance for any patient fit for rescue reintervention . SVS recommends a baseline contrast-enhanced CT angiogram within 30 days of EVAR; if there is no endoleak and no sac enlargement at one month, imaging repeats at 12 months and then converts to colour duplex ultrasound annually, reserving CT angiography for a new endoleak or sac growth. ESVS follows the same logic: first-year CT angiography, then annual duplex ultrasound in stable patients, reverting to CT angiography if surveillance detects an abnormality.

Areas of controversy

Screening indications for women remain unsettled. Due to an imprecise trial base and lower population prevalence, recommendations diverge across organizations, precluding a single standardized approach .

Morphologic repair triggers also lack strict numeric boundaries. While saccular morphology commands earlier intervention, guidelines have not established a universal dimensional offset to define early repair precisely . Similarly, the use of pharmacotherapy, including statins and metformin, for aneurysm growth modification relies solely on observational signals, as no randomized trials have confirmed an aneurysm-specific mechanism or benefit .

References

  1. 1.
    Reporting standards for endovascular aortic aneurysm repair. 2002.
    PubMed-indexed article2002

    Reporting standards for endovascular aortic aneurysm repair. 2002. doi:10.1067/mva.2002.123763.

    PubMedDOI
  2. 2.
    ACR Appropriateness Criteria® Pulsatile Abdominal Mass, Suspected Abdominal Aortic Aneurysm: 2023 Update. Journal of the American College of Radiology : JACR. 2023.
    PubMed-indexed articleClinical practice guideline2023

    ACR Appropriateness Criteria® Pulsatile Abdominal Mass, Suspected Abdominal Aortic Aneurysm: 2023 Update. Journal of the American College of Radiology : JACR. 2023. doi:10.1016/j.jacr.2023.08.010.

    PubMedDOI
  3. 3.
    The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial.
    PubMed-indexed articleRandomized controlled trial2002
    PubMedDOI
  4. 4.
    Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ (Clinical research ed.). 2009.
    PubMed-indexed articleRandomized controlled trial2009

    Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ (Clinical research ed.). 2009. doi:10.1136/bmj.b2307.

    PubMedDOI
  5. 5.
    Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. 2012.
    PubMed-indexed articleRandomized controlled trial2012

    Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. 2012. doi:10.1002/bjs.8897.

    PubMedDOI
  6. 6.
    Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev. 2007.
    PubMed-indexed articleMeta-analysis / systematic review2007

    Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev. 2007. doi:10.1002/14651858.CD002945.pub2. PMID:17443519.

    PubMedDOI
  7. 7.
    Primary Care Screening for Abdominal Aortic Aneurysm: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019.
    PubMed-indexed articleMeta-analysis / systematic review2019

    Primary Care Screening for Abdominal Aortic Aneurysm: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. doi:10.1001/jama.2019.17021. PMID:31821436.

    PubMedDOI
  8. 8.
    The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. 2018.
    PubMed-indexed articleClinical practice guideline2018

    The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. 2018. doi:10.1016/j.jvs.2017.10.044.

    PubMedDOI
  9. 9.
    Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. 2019.
    PubMed-indexed articleClinical practice guideline2019

    Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. 2019. doi:10.1001/jama.2019.18928.

    PubMedDOI
  10. 10.
    Immediate repair compared with surveillance of small abdominal aortic aneurysms. 2002.
    DOI publisher routeRandomized controlled trial2002

    Immediate repair compared with surveillance of small abdominal aortic aneurysms. 2002. doi:10.1056/nejmoa012573.

    PubMedDOISource
  11. 11.
    Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. 2024.
    PubMed-indexed articleClinical practice guideline2024

    Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. 2024. doi:10.1016/j.ejvs.2023.11.002.

    PubMedDOI
  12. 12.
    Editor's Choice - Systematic Review and Meta-Analysis of Contemporary Abdominal Aortic Aneurysm Growth Rates. Eur J Vasc Endovasc Surg. 2024.
    PubMed-indexed articleMeta-analysis / systematic review2024

    Editor's Choice - Systematic Review and Meta-Analysis of Contemporary Abdominal Aortic Aneurysm Growth Rates. Eur J Vasc Endovasc Surg. 2024. doi:10.1016/j.ejvs.2023.09.039. PMID:37777049.

    PubMedDOI
  13. 13.
    Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2018.
    PubMed-indexed articleMeta-analysis / systematic review2018

    Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2018. doi:10.1161/jaha.118.008657.

    PubMedDOI
  14. 14.
    Extended screening guidelines for the diagnosis of abdominal aortic aneurysm. Journal of vascular surgery. 2020.
    PubMed-indexed articleClinical practice guideline2020

    Extended screening guidelines for the diagnosis of abdominal aortic aneurysm. Journal of vascular surgery. 2020. doi:10.1016/j.jvs.2020.03.047.

    PubMedDOI
  15. 15.
    Effects of Fluoroquinolones on Aortic Aneurysm or Dissection Processes: A Systematic Review. 2026.
    PubMed-indexed articleMeta-analysis / systematic review2026

    Effects of Fluoroquinolones on Aortic Aneurysm or Dissection Processes: A Systematic Review. 2026. doi:10.31083/rcm43656.

    PubMedDOI
  16. 16.
    Editor's Choice - Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events: a Systematic Review and Meta-Analysis. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2021.
    PubMed-indexed articleMeta-analysis / systematic review2021

    Editor's Choice - Association Between Metformin Prescription and Abdominal Aortic Aneurysm Growth and Clinical Events: a Systematic Review and Meta-Analysis. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2021. doi:10.1016/j.ejvs.2021.06.013.

    PubMedDOI
  17. 17.
    Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm. 2026.
    PubMed-indexed articleReview2026

    Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm. 2026. doi:10.1186/s40842-026-00275-7.

    PubMedDOI
  18. 18.
    Sex Differences in Outcomes After Endovascular Abdominal Aortic Aneurysm Repair. 2026.
    PubMed-indexed articleMeta-analysis / systematic review2026

    Sex Differences in Outcomes After Endovascular Abdominal Aortic Aneurysm Repair. 2026. doi:10.31083/rcm47920.

    PubMedDOI
  19. 19.
    Systematic review and meta-analysis of the prevalence of abdominal aortic aneurysm in Asian populations. J Vasc Surg. 2021.
    PubMed-indexed articleMeta-analysis / systematic review2021

    Systematic review and meta-analysis of the prevalence of abdominal aortic aneurysm in Asian populations. J Vasc Surg. 2021. doi:10.1016/j.jvs.2020.08.140. PMID:32987145.

    PubMedDOI
  20. 20.
    Clinical Practice Guidelines of the Korean Society for Vascular Surgery for the Management of Abdominal Aortic Aneurysms: Focused on 18 Key Clinical Questions. 2026.
    PubMed-indexed articleClinical practice guideline2026

    Clinical Practice Guidelines of the Korean Society for Vascular Surgery for the Management of Abdominal Aortic Aneurysms: Focused on 18 Key Clinical Questions. 2026. doi:10.5758/vsi.250023.

    PubMedDOI
  21. 21.
    Ultrasonography for endoleak detection after endoluminal abdominal aortic aneurysm repair. Cochrane Database Syst Rev. 2017.
    PubMed-indexed articleMeta-analysis / systematic review2017

    Ultrasonography for endoleak detection after endoluminal abdominal aortic aneurysm repair. Cochrane Database Syst Rev. 2017. doi:10.1002/14651858.CD010296.pub2. PMID:28598495.

    PubMedDOI
  22. 22.
    Abdominal Aortic Aneurysm Diameter versus Volume: A Systematic Review. Biomedicines. 2023.
    PubMed-indexed articleMeta-analysis / systematic review2023

    Abdominal Aortic Aneurysm Diameter versus Volume: A Systematic Review. Biomedicines. 2023. doi:10.3390/biomedicines11030941.

    PubMedDOI
  23. 23.
    Late Rupture of Abdominal Aortic Aneurysm After Previous Endovascular Repair: A Systematic Review and Meta-analysis. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 2015.
    PubMed-indexed articleMeta-analysis / systematic review2015

    Late Rupture of Abdominal Aortic Aneurysm After Previous Endovascular Repair: A Systematic Review and Meta-analysis. Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists. 2015. doi:10.1177/1526602815601405.

    PubMedDOI
  24. 24.
    Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. J Vasc Surg. 2003;37(5):1106-1117.
    PubMed-indexed article2003

    Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. J Vasc Surg. 2003;37(5):1106-1117. doi:10.1067/mva.2003.363.

    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions